Sauerbruch T, Neubrand M
Medical Department, University of Bonn, Germany.
Prog Liver Dis. 1992;10:193-218.
Nonsurgical management of gallstones has made considerable progress within the past 20 years. More than 95% of all patients with bile duct stones can be treated successfully by peroral endoscopic or percutaneous techniques. In the case of very large or impacted calculi, intracorporeal or extracorporeal lithotripsy is available (Figure 9-10). Mortality from these approaches is low (in the range of 1%) despite the fact that most patients are elderly and frail, and open surgery is rarely required. While nonsurgical management of bile duct stones is commonly accepted, there is disagreement as to whether gallbladder stones should be managed nonsurgically, especially in view of the introduction of laparoscopic cholecystectomy. For patients in good general health who are willing to undergo surgery, removal of the gallbladder is the treatment of choice. However, there are some patients in whom a nonsurgical procedure ought to be considered. These are patients with a patent cystic duct, a functioning gallbladder, and symptomatic, radiolucent stones who can be scheduled for elective treatment. In patients with small floating stones, solitary radiolucent stones or even multiple large stones with a CT density lower than 50 HU, the chance of complete clearance of the gallbladder ranges between 80% and 90% using oral dissolution therapy, direct contact dissolution, or a combination of extracorporeal lithotripsy and dissolution. Each method has its ideal candidates (Table 9-1). The overall percentage of patients with gallstones for these nonsurgical therapeutic options is probably not higher than 20%. Therefore, the impact on surgery is still minor. Controlled clinical comparisons of the different therapies are lacking at the moment. However, these approaches have already stimulated further research into the pathogenesis of gallbladder stone disease and will no doubt undergo further improvement. Drugs that, in addition to ursodeoxycholic acid, further reduce cholesterol saturation in bile such as 3-hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors are already under investigation for oral treatment of gallstones in combination with bile acids. Further studies will also clarify the influence of gallbladder motility and certain bile constituents, such as proteins, on clearance of gallstones and recurrence after successful nonsurgical management. Thus, nonsurgical options, which obviate the necessity for general anesthesia and eliminate the risk of bile duct injury, will certainly continue to play a role in the management of gallbladder stones.
在过去20年里,胆结石的非手术治疗取得了长足进展。超过95%的胆管结石患者可通过经口内镜或经皮技术成功治疗。对于非常大的结石或嵌顿结石,可采用体内或体外碎石术(图9-10)。尽管大多数患者年老体弱,但这些治疗方法的死亡率较低(在1%左右),很少需要进行开放手术。虽然胆管结石的非手术治疗已被广泛接受,但对于胆囊结石是否应采用非手术治疗仍存在分歧,尤其是考虑到腹腔镜胆囊切除术的引入。对于一般健康状况良好且愿意接受手术的患者,切除胆囊是首选治疗方法。然而,有些患者应考虑采用非手术治疗。这些患者的胆囊管通畅、胆囊功能正常,且有症状的透X线结石,可安排择期治疗。对于有小的漂浮结石、孤立的透X线结石甚至多个CT密度低于50 HU的大结石的患者,采用口服溶石疗法、直接接触溶石或体外碎石与溶石相结合的方法,胆囊结石完全清除的几率在80%至90%之间。每种方法都有其理想的适用患者(表9-1)。这些非手术治疗方案适用于胆结石患者的总体比例可能不高于20%。因此,对手术的影响仍然较小。目前缺乏不同疗法的对照临床比较。然而,这些方法已经激发了对胆囊结石病发病机制的进一步研究,并且无疑会得到进一步改进。除熊去氧胆酸外,还能进一步降低胆汁中胆固醇饱和度的药物,如3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,已在研究中用于与胆汁酸联合口服治疗胆结石。进一步的研究还将阐明胆囊运动和某些胆汁成分(如蛋白质)对胆结石清除及非手术治疗成功后复发的影响。因此,避免全身麻醉必要性并消除胆管损伤风险的非手术选择,肯定会在胆囊结石的治疗中继续发挥作用。